123 related articles for article (PubMed ID: 8630880)
1. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model.
Davol P; Beitz JG; Mohler M; Ying W; Cook J; Lappi DA; Frackelton AR
Cancer; 1995 Jul; 76(1):79-85. PubMed ID: 8630880
[TBL] [Abstract][Full Text] [Related]
2. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model.
Davol P; Frackelton AR
J Urol; 1996 Sep; 156(3):1174-9. PubMed ID: 8709341
[TBL] [Abstract][Full Text] [Related]
3. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
4. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance.
Davol PA; Frackelton AR
Prostate; 1999 Aug; 40(3):178-91. PubMed ID: 10398280
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo.
Beitz JG; Davol P; Clark JW; Kato J; Medina M; Frackelton AR; Lappi DA; Baird A; Calabresi P
Cancer Res; 1992 Jan; 52(1):227-30. PubMed ID: 1309225
[TBL] [Abstract][Full Text] [Related]
6. Anti-B16-F10 melanoma activity of a basic fibroblast growth factor-saporin mitotoxin.
Ying W; Martineau D; Beitz J; Lappi DA; Baird A
Cancer; 1994 Aug; 74(3):848-53. PubMed ID: 8039113
[TBL] [Abstract][Full Text] [Related]
7. Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
Davol PA; Garza S; Frackelton AR
Cancer; 1999 Nov; 86(9):1733-41. PubMed ID: 10547546
[TBL] [Abstract][Full Text] [Related]
8. Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein.
Farb A; Lee SJ; Min DH; Parandoosh Z; Cook J; McDonald J; Pierce GF; Virmani R
Circ Res; 1997 Apr; 80(4):542-50. PubMed ID: 9118485
[TBL] [Abstract][Full Text] [Related]
9. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
[TBL] [Abstract][Full Text] [Related]
10. The basic fibroblast growth factor-saporin mitotoxin impairs in vivo skeletal regeneration following injury.
Lefaucheur JP; Sébille A
Neuromuscul Disord; 1993; 3(5-6):367-70. PubMed ID: 8186677
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effects of basic FGF and heparin binding EGF conjugated with cytotoxin saporin on vascular cell cultures.
Chen C; Li J; Micko CJ; Pierce GF; Cunningham MR; Lumsden AB
J Surg Res; 1998 Feb; 75(1):35-41. PubMed ID: 9614854
[TBL] [Abstract][Full Text] [Related]
12. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
[TBL] [Abstract][Full Text] [Related]
13. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor complexed to the cytotoxin saporin is growth inhibitory but not cytotoxic for embryonal carcinoma cells.
Miller K; Wilder PJ; Rizzino A
Cytotechnology; 1993; 13(2):69-78. PubMed ID: 7764580
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effect of basic fibroblast growth factor-saporin mitotoxin on keratocytes in culture.
Wee WR; Parandoosh Z; Sakamoto T; Caton M; Nova M; McDonnell PJ
Korean J Ophthalmol; 1996 Jun; 10(1):1-7. PubMed ID: 8755195
[TBL] [Abstract][Full Text] [Related]
17. Reducing the heterogeneity of chemically conjugated targeted toxins: homogeneous basic FGF-saporin.
Lappi DA; Matsunami R; Martineau D; Baird A
Anal Biochem; 1993 Aug; 212(2):446-51. PubMed ID: 8214586
[TBL] [Abstract][Full Text] [Related]
18. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor.
Lappi DA; Maher PA; Martineau D; Baird A
J Cell Physiol; 1991 Apr; 147(1):17-26. PubMed ID: 1645359
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-2-toxin induced cytotoxicity: differential sensitivity of co-cultured vascular smooth muscle cells and endothelial cells.
Lin PH; Ren D; Hirko MK; Kang SS; Pierce GF; Greisler HP
Atherosclerosis; 1998 Apr; 137(2):277-89. PubMed ID: 9622271
[TBL] [Abstract][Full Text] [Related]
20. The biologic effects of growth factor-toxin conjugates in models of vascular injury depend on dose, mode of delivery, and animal species.
Yu C; Cunningham M; Rogers C; Dinbergs ID; Edelman ER
J Pharm Sci; 1998 Nov; 87(11):1300-4. PubMed ID: 9811480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
